Allergan Hits Watson With Patent Suit Over Combigan

Law360, New York (September 03, 2010, 11:39 AM ET) -- Allergan Inc. has launched another patent infringement suit over its Combigan eye medication, targeting Watson Pharmaceutical Inc.'s efforts to market a generic version of the glaucoma drug.

Allergen filed suit in the U.S. District Court for the Eastern District of Texas on Thursday, claiming that Watson infringed four patents when it filed an abbreviated new drug application with the U.S. Food and Drug Administration for generic Combigan.

According to the complaint, the plaintiff received a letter from Watson on July 30 saying that it had filed...
To view the full article, register now.